264 related articles for article (PubMed ID: 15580502)
1. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation.
Lee JH; Choi SJ; Lee JH; Kim SE; Park CJ; Chi HS; Lee MS; Lee JS; Kim WK; Lee KH
Ann Hematol; 2005 May; 84(5):321-30. PubMed ID: 15580502
[TBL] [Abstract][Full Text] [Related]
2. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation for severe aplastic anemia.
Lee JH; Lee KH; Choi SJ; Min YJ; Kim JG; Kim S; Lee JS; Kim SH; Park CJ; Chi HS; Kim WK
Bone Marrow Transplant; 2000 Sep; 26(6):657-62. PubMed ID: 11041568
[TBL] [Abstract][Full Text] [Related]
3. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity.
Hassan M; Ljungman P; Ringdén O; Hassan Z; Oberg G; Nilsson C; Békassy A; Bielenstein M; Abdel-Rehim M; Georén S; Astner L
Bone Marrow Transplant; 2000 May; 25(9):915-24. PubMed ID: 10800057
[TBL] [Abstract][Full Text] [Related]
4. Hepatic veno-occlusive disease post-bone marrow transplantation in children conditioned with busulfan and cyclophosphamide: incidence, risk factors, and clinical outcome.
Ozkaynak MF; Weinberg K; Kohn D; Sender L; Parkman R; Lenarsky C
Bone Marrow Transplant; 1991 Jun; 7(6):467-74. PubMed ID: 1908340
[TBL] [Abstract][Full Text] [Related]
5. Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis.
Styler MJ; Crilley P; Biggs J; Moul J; Copelan E; Topolsky D; Avalos B; Penza S; Sabol P; Downs K; Szer J; Brodsky I; Marks DI
Bone Marrow Transplant; 1996 Jul; 18(1):171-6. PubMed ID: 8832011
[TBL] [Abstract][Full Text] [Related]
6. Association of busulfan area under the curve with veno-occlusive disease following BMT.
Dix SP; Wingard JR; Mullins RE; Jerkunica I; Davidson TG; Gilmore CE; York RC; Lin LS; Devine SM; Geller RB; Heffner LT; Hillyer CD; Holland HK; Winton EF; Saral R
Bone Marrow Transplant; 1996 Feb; 17(2):225-30. PubMed ID: 8640171
[TBL] [Abstract][Full Text] [Related]
7. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
Bleyzac N; Souillet G; Magron P; Janoly A; Martin P; Bertrand Y; Galambrun C; Dai Q; Maire P; Jelliffe RW; Aulagner G
Bone Marrow Transplant; 2001 Oct; 28(8):743-51. PubMed ID: 11781625
[TBL] [Abstract][Full Text] [Related]
8. Changes in hemostatic parameters in hepatic veno-occlusive disease following bone marrow transplantation.
Park YD; Yasui M; Yoshimoto T; Chayama K; Shimono T; Okamura T; Inoue M; Yumura-Yagi K; Kawa-Ha K
Bone Marrow Transplant; 1997 May; 19(9):915-20. PubMed ID: 9156266
[TBL] [Abstract][Full Text] [Related]
9. Relevance of proteins C and S, antithrombin III, von Willebrand factor, and factor VIII for the development of hepatic veno-occlusive disease in patients undergoing allogeneic bone marrow transplantation: a prospective study.
Lee JH; Lee KH; Kim S; Lee JS; Kim WK; Park CJ; Chi HS; Kim SH
Bone Marrow Transplant; 1998 Nov; 22(9):883-8. PubMed ID: 9827816
[TBL] [Abstract][Full Text] [Related]
10. Improved results of allogeneic bone marrow transplantation for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy.
Vaughan WP; Dennison JD; Reed EC; Klassen L; McGuire TR; Sanger WG; Kumar PP; Warkentin PI; Gordon BG; Bierman PJ
Bone Marrow Transplant; 1991 Dec; 8(6):489-95. PubMed ID: 1790429
[TBL] [Abstract][Full Text] [Related]
11. Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34(+) positive selection.
Moscardó F; Sanz GF; de La Rubia J; Jiménez C; Saavedra S; Regadera A; Andreu R; García I; Plumé G; Martínez J; Martín G; Jarque I; Sanz MA
Bone Marrow Transplant; 2001 May; 27(9):983-8. PubMed ID: 11436110
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation.
Rosenthal J; Sender L; Secola R; Killen R; Millerick M; Murphy L; Cairo MS
Bone Marrow Transplant; 1996 Jul; 18(1):185-91. PubMed ID: 8832013
[TBL] [Abstract][Full Text] [Related]
13. Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia.
Przepiorka D; Khouri I; Thall P; Mehra R; Lee MS; Ippoliti C; Giralt S; Gajewski J; van Besien K; Andersson B; Körbling M; Deisseroth AB; Champlin R
Bone Marrow Transplant; 1999 May; 23(10):977-81. PubMed ID: 10373061
[TBL] [Abstract][Full Text] [Related]
14. [Measurement of busulfan concentration in plasma and spinal fluid from transplant patients pretreated with busulfan and cyclophosphamide].
Okamoto T; Tamura A; Miyazaki E; Fujimori Y; Inoue N; Takemoto Y; Kohsaki M; Kanamaru A; Kakishita E; Nagai K
Rinsho Ketsueki; 1992 Jun; 33(6):796-800. PubMed ID: 1433919
[TBL] [Abstract][Full Text] [Related]
15. Toxicity of high-dose busulphan and cyclophosphamide as conditioning therapy for allogeneic bone marrow transplantation in adults with haematological malignancies.
Bandini G; Belardinelli A; Rosti G; Calori E; Motta MR; Rizzi S; Benini C; Tura S
Bone Marrow Transplant; 1994 May; 13(5):577-81. PubMed ID: 8054910
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide.
Lee JH; Lee KH; Lee JH; Kim S; Seol M; Park CJ; Chi HS; Kang W; Kim ST; Kim WK; Lee JS
Br J Haematol; 2002 Sep; 118(4):1087-94. PubMed ID: 12199790
[TBL] [Abstract][Full Text] [Related]
17. Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation.
Morris JD; Harris RE; Hashmi R; Sambrano JE; Gruppo RA; Becker AT; Morris CL
Bone Marrow Transplant; 1997 Nov; 20(10):871-8. PubMed ID: 9404929
[TBL] [Abstract][Full Text] [Related]
18. Predictive markers for hepatic veno-occlusive disease after hematopoietic stem cell transplantation in adults: a prospective single center study.
Tanikawa S; Mori S; Ohhashi K; Akiyama H; Sasaki T; Kaku H; Hiruma K; Matsunaga T; Morita T; Sakamaki H
Bone Marrow Transplant; 2000 Oct; 26(8):881-6. PubMed ID: 11081389
[TBL] [Abstract][Full Text] [Related]
19. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality.
Kashyap A; Wingard J; Cagnoni P; Roy J; Tarantolo S; Hu W; Blume K; Niland J; Palmer JM; Vaughan W; Fernandez H; Champlin R; Forman S; Andersson BS
Biol Blood Marrow Transplant; 2002; 8(9):493-500. PubMed ID: 12374454
[TBL] [Abstract][Full Text] [Related]
20. Laboratory markers of veno-occlusive disease in the course of bone marrow and subsequent liver transplantation.
Salat C; Holler E; Wolf C; Kolb HJ; Reinhardt B; Pihusch R; Krämling HJ; Heinemann V; Haller M; Hiller E
Bone Marrow Transplant; 1997 Mar; 19(5):487-90. PubMed ID: 9052916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]